• Study Resource
  • Explore
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
amyotrophic lateral sclerosis (als) – opportunity analysis and
amyotrophic lateral sclerosis (als) – opportunity analysis and

... with ALS, as well as the drug currently used in its treatment, makes it challenging to compare these ...
Перевод с русского языка на английский язык Приказа
Перевод с русского языка на английский язык Приказа

... 3) generated medicinal product (generic) is a medicinal product similar with the original product in terms of the active substances composition and dosage form, coming on the market after expiry of protection document validity for the original drug, or on the ground of a license agreement; 4) Applic ...
AusPAR: Lixisenatide - Therapeutic Goods Administration
AusPAR: Lixisenatide - Therapeutic Goods Administration

... endotoxins and chiral purity. Acceptable method and validation details were provided. Data were provided showing that the drug substance is stable for up to 18 months when stored at -20°C (protected from light) and on this basis the company has proposed a retest period of 30 months. Drug product The ...
10 November 2014 EMA/CHMP/SAWP/72894/2008 Revision 1: January 2012
10 November 2014 EMA/CHMP/SAWP/72894/2008 Revision 1: January 2012

... is only intended to provide the applicant with the opportunity to clarify the meaning of the qualification advice on future protocols and methods for further method development towards qualification procedure that is perceived as being not clear or precise enough. Any new information will only be co ...
Enhancement of naturally acquired immunity against malaria by
Enhancement of naturally acquired immunity against malaria by

Use of antihistamines in pediatrics
Use of antihistamines in pediatrics

... are required. In all the age groups the safety data are of greater importance, and studies involving one to three months of follow-up are demanded, with special attention to the adverse effects upon growth. The first-generation antihistamines have never been adequately studied for pediatric age grou ...
The Ophthalmology Market
The Ophthalmology Market

187 Formulation and Evaluation of Rofecoxib Tablets
187 Formulation and Evaluation of Rofecoxib Tablets

... compressed and wet granulated glibenclamide tablets were prepared they gave only 35% and 40% drug dissolved respectively. However, grinding of glibenclamide with β-CD could markedly enhance the release of the drug from the prepared tablets (7). ROF is a selective cycloxygenase-2-inhibitor administer ...
focusing in on adderall - Institute for Food Laws and Regulations
focusing in on adderall - Institute for Food Laws and Regulations



Ibuprofen is a non-steriodal anti-inflammatory drug with established
Ibuprofen is a non-steriodal anti-inflammatory drug with established

... used is paracetamol. Licensed doses of ibuprofen vary between countries, as they do for paracetamol. For all licensed doses, ibuprofen has been shown to be at least as effective as paracetamol in treating fever. There is evidence that, at some licensed doses, ibuprofen is superior to paracetamol. As ...
The History and Implications of Testing Thalidomide on
The History and Implications of Testing Thalidomide on

... Robustness and redundancy of components and pathways.[711] Robustness implies the system is resistant to change. In the case of animal models, deleting a gene may have lethal effects or minimal effects depending on the species and even the strain used. Predicting the function of a gene for species ...
DRUG ELIMINATION THE KIDNEY Anatomic Considerations
DRUG ELIMINATION THE KIDNEY Anatomic Considerations

... Glomerular filtration is a unidirectional process that occurs for most small molecules (MW < 500), including undissociated (nonionized) and dissociated (ionized) drugs. Protein-bound drugs behave as large molecules and do not get filtered at the glomerulus. The major driving force for glomerular fil ...
The impact of polypharmacology on chemical biology Albert Antolín Hernández
The impact of polypharmacology on chemical biology Albert Antolín Hernández

... with more than one protein, a behavior that is commonly referred to as polypharmacology. This finding is starting to have a true impact on the drug discovery process, transforming it into a more holistic endeavor. In contrast, chemical biology continues to be a reductionist discipline, still regardi ...
Pharmacokinetics and pharmacodynamics of the - e
Pharmacokinetics and pharmacodynamics of the - e

... exceeds serum by many fold.17,22 Penetration as assessed by a 3 h post-dose concentration measurement after a single peri-operative dose of doxycycline in orthopaedics indicated levels below that of serum in bone, skin, fat, tendons and muscle.40 Concentrations are highest in the liver, kidney and d ...
Biowaiver extension potential to BCS Class III high solubility
Biowaiver extension potential to BCS Class III high solubility

... Thus, it is evident that if the formulation of metformin IR product is rapid dissolving, dissolution will not affect availability of metformin. Using the rationale of the BCS, it can be argued that biowaivers can be granted for metformin IR products on the basis of in vitro dissolution profiles. The ...
approved by Order No. 200n of April 01, 2016 of the Ministry of
approved by Order No. 200n of April 01, 2016 of the Ministry of

AusPAR: Prednisone
AusPAR: Prednisone

... this application sought the opinion of the Advisory Committee on Prescription Medicines (ACPM) as to whether the indication which is sought is consistent with the already approved indication for rheumatoid arthritis. According to the Product Information document (PI), the initial daily dose is 10 mg ...
Role of Pharmacokinetics and Metabolism in Drug Discovery and
Role of Pharmacokinetics and Metabolism in Drug Discovery and

Use these links to rapidly review the document TABLE OF
Use these links to rapidly review the document TABLE OF

... which focus on the adenosine-cancer axis to modulate an immune response. Our lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. In January 2016, we began enrolling patients in a large expansion cohort trial for CPI-444. Thi ...
annexure – ii - Rajiv Gandhi University of Health Sciences
annexure – ii - Rajiv Gandhi University of Health Sciences

... Data will be obtained from the literature search and experimental work, which includes preformulation studies, formulation, product evaluation, optimization and subjecting the formulation to accelerated stability studies. Data on drugs ...
February 2, 2010 Dockets Management Branch (HFA
February 2, 2010 Dockets Management Branch (HFA

... ADA data. It merely suggests that ADA incidence and titer data are of clinical utility. Therefore the current guidance is lacking in bridging the key concepts of quantitative and qualitative results that provide clinically relevant information for clinicians on how to interpret immunogenicity data w ...
Memorandum 0429 '03  JAN 27  P2:21
Memorandum 0429 '03 JAN 27 P2:21

... recommendedor suggested,will reasonablybe expectedto be safe. You state in your submissionthat “Millions of people have consumedmelatonin as a dietary supplementover the last ten years in dosagesfrom l-20 mg. The recommendeddosageof l-2 mg N-acetylserotonin is basedon the approximatequantities of ex ...
INTRAVENOUS INFUSION: INTRODUCTION ONE
INTRAVENOUS INFUSION: INTRODUCTION ONE

... As stated earlier, the rate of drug leaving the body is equal to the rate of drug entering the body (infusion rate) at steady state (). In other w ords, there is no net change in the amount of drug in the body, D B, as a function of time during steady state. Drug elimination occurs according to firs ...
State of the evidence from oral and topical PrEP efficacy
State of the evidence from oral and topical PrEP efficacy

... Demonstration Projects, Regulatory Approval, Normative Guidance and Government Support • Demonstration Projects ...
< 1 ... 11 12 13 14 15 16 17 18 19 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report